Share on StockTwits

Shares of Teleflex (NYSE:TFX) have earned a consensus recommendation of “Buy” from the eleven brokerages that are presently covering the stock, American Banking reports. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $108.17.

Several analysts have recently commented on the stock. Analysts at Barclays raised their price target on shares of Teleflex from $98.00 to $105.00 in a research note on Monday. They now have an “equal weight” rating on the stock. Separately, analysts at Raymond James set a $115.00 price target on shares of Teleflex in a research note on Monday. Finally, analysts at Morgan Stanley reiterated an “overweight” rating on shares of Teleflex in a research note on Monday. They now have a $114.00 price target on the stock, up previously from $106.00.

Teleflex (NYSE:TFX) opened at 100.65 on Tuesday. Teleflex has a one year low of $73.83 and a one year high of $103.51. The stock’s 50-day moving average is $95.20 and its 200-day moving average is $89.07. The company has a market cap of $4.352 billion and a P/E ratio of 29.15.

Teleflex (NYSE:TFX) last announced its earnings results on Friday, February 21st. The company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.09. The company had revenue of $450.50 million for the quarter, compared to the consensus estimate of $437.06 million. On average, analysts predict that Teleflex will post $5.50 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Friday, March 14th. Shareholders of record on Tuesday, March 4th will be given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 1.35%. The ex-dividend date of this dividend is Friday, February 28th.

Teleflex Incorporated (NYSE:TFX) is a global provider of medical technology products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.